Makara Journal of Science
Volume 24
Issue 4 December

Article 3

12-20-2020

Lemongrass (Cymbopogon citratus) Ethanolic Extract Exhibited
Activities That Inhibit -glucosidase Enzymes and Postprandial
Blood Glucose Elevation
Maria Dewi Puspitasari Tirtaningtyas Gunawan Puteri
Department of Food Technology, Faculty of Life Sciences and Technology, Swiss German University,
Tangerang 15143, Indonesia, maria.gunawanputeri@sgu.ac.id

Felicia Melissa Tjiptadi
Department of Food Technology, Faculty of Life Sciences and Technology, Swiss German University,
Tangerang 15143, Indonesia

Phebe Hendra
Faculty of Pharmacy, Universitas Sanata Dharma, Yogyakarta, 55282, Indonesia

Filiana Santoso
Department of Food Technology, Faculty of Life Sciences and Technology, Swiss German University,
Tangerang 15143, Indonesia
Follow this
and additional works at: https://scholarhub.ui.ac.id/science
Zalinar
Udin
Research Center for Chemistry, Indonesian Institut of Science (LIPI-Kimia), Banten 15314, Indonesia
Part of the Alternative and Complementary Medicine Commons, Medicinal Chemistry and
Pharmaceutics Commons, Other Food Science Commons, and the Other Plant Sciences Commons

See next page for additional authors

Recommended Citation
Gunawan Puteri, Maria Dewi Puspitasari Tirtaningtyas; Tjiptadi, Felicia Melissa; Hendra, Phebe; Santoso,
Filiana; Udin, Zalinar; Artanti, Nina; and Florence Ignatia, Florence Ignatia (2020) "Lemongrass
(Cymbopogon citratus) Ethanolic Extract Exhibited Activities That Inhibit -glucosidase Enzymes and
Postprandial Blood Glucose Elevation," Makara Journal of Science: Vol. 24 : Iss. 4 , Article 3.
DOI: 10.7454/mss.v24i4.1154
Available at: https://scholarhub.ui.ac.id/science/vol24/iss4/3

This Article is brought to you for free and open access by the Universitas Indonesia at UI Scholars Hub. It has been
accepted for inclusion in Makara Journal of Science by an authorized editor of UI Scholars Hub.

Lemongrass (Cymbopogon citratus) Ethanolic Extract Exhibited Activities That
Inhibit -glucosidase Enzymes and Postprandial Blood Glucose Elevation
Authors
Maria Dewi Puspitasari Tirtaningtyas Gunawan Puteri, Felicia Melissa Tjiptadi, Phebe Hendra, Filiana
Santoso, Zalinar Udin, Nina Artanti, and Florence Ignatia Florence Ignatia

This article is available in Makara Journal of Science: https://scholarhub.ui.ac.id/science/vol24/iss4/3

Makara Journal of Science, 24/4 (2020), 219−227
doi: 10.7454/mss.v24i4.1154

Lemongrass (Cymbopogon citratus) Ethanolic Extract Exhibited Activities That
Inhibit -glucosidase Enzymes and Postprandial Blood Glucose Elevation
Maria Dewi Puspitasari Tirtaningtyas Gunawan-Puteri1*, Felicia Melissa Tjiptadi1, Phebe Hendra2,
Filiana Santoso1, Zalinar Udin3, Nina Artanti3, and Florence Ignatia1
1. Department of Food Technology, Faculty of Life Sciences and Technology, Swiss German University,
Tangerang 15143, Indonesia
2. Faculty of Pharmacy, Universitas Sanata Dharma, Yogyakarta, 55282, Indonesia
3. Research Center for Chemistry, Indonesian Institut of Science (LIPI-Kimia), Banten 15314, Indonesia
*

E-mail: maria.gunawanputeri@sgu.ac.id

Received January 22, 2020 | Accepted July 15, 2020

Abstract
Lemongrass is a common ingredient in Indonesian traditional herbal medicine that potently inhibits carbohydrate hydrolysis. In this study, the in vitro α-glucosidase inhibitory (AGI) activity of lemongrass was compared with its in vivo
activity to retard postprandial blood glucose elevation, and the bioactive compounds responsible for these activities
were observed. Both water and ethanolic extracts of lemongrass (WLG and ELG, respectively) were tested in vitro for
its inhibition of the sucrose and maltose hydrolyzing activities of rat intestinal glucosidase. ELG was observed to exert
higher inhibitory activities (Sucrase IC50 = 8.74 mg/mL; Maltase IC50 = 18.93 mg/mL) than WLG. ELG was evaluated
for its in vivo activity to retard blood glucose elevation in mice after sucrose, maltose, and glucose consumption. ELG
was also fractionated using activity-guided chromatography, followed by liquid chromatography–mass spectrometry
and high-performance liquid chromatography (HPLC). In vivo sugar tolerance test confirmed the AGI activity in a nondose-dependent manner and showed potential additional mechanisms that may prevent postprandial hyperglycemia. The
active principles were acquired in methanol-soluble fraction and purified using preparative thin-layer chromatography.
HPLC analysis with commercial standards identified caffeic acid and kaempferol as the compounds responsible for the
bioactivity of ELG. Results showed that lemongrass has the potential as herbal medicine ingredient in the management
of diabetes.
Keywords: α-glucosidase inhibitor, Cymbopogon citratus, diabetes, Indonesian traditional medicine, lemongrass

beverage and food recipes that are also known to have
various health benefits [7, 8]. Because of its strong roots
that hold the soil, lemongrass plantations in Indonesia
have also been known to prevent soil erosion in terrace
farming. Commercialization of lemongrass as scientificbased herbal medicine, known as obat herbal terstandar
(OHT) in Indonesia, is expected to increase both the
value and the plantation of this plant [9]. The National
Agency of Drug and Food Control of the Republic of
Indonesia stated that herbal medicine registration as
OHT must include the identification of active compounds as biomarkers, use of biomarker content for
product quality control, and in vivo confirmatory tests
of its activity and toxicity [10].

Introduction
The treatment of diabetes mellitus has been an increasing concern in Indonesia, as it became the fifth country
with the highest prevalence of diabetes after China, India, Brazil, and the US [1]. The α-glucosidase inhibitor
(AGI) inhibits the hydrolysis of polysaccharides and
disaccharides in the small intestine, thereby delaying the
spike of postprandial blood glucose after meals [2–5].
AGIs can be a reasonable option as the first-line drug in
the treatment of patients with diabetes mellitus type 2 as
it specifically targets postprandial hyperglycemia. AGIs
are also expected to cause no hypoglycemic events or
other life-threatening events, even at overdoses, and no
weight gain [6].

Ethnopharmacological and pharmacological investigations of lemongrass summarized the uses and potential
functions of the essential oil and water extract of
lemongrass (WLG) for various health benefits [8], in-

Lemongrass (Cymbopogon citratus) is widely cultivated
in tropical and subtropical countries. Lemongrass is a
popular spice and flavoring agent in various traditional
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cluding the hypoglycemic effect of its fresh leaf aqueous extract [11] and in vitro antidiabetic activity of its
essential oil [12]. Previous research on the exploration
of Indonesian plant activities also reported the AGI activity of aqueous and methanolic extracts of lemongrass
[13–15]. However, in vivo activity confirmation and
evaluation of active compounds responsible for the AGI
activity have not been conducted.
Common preparation methods for medicinal herbs in
the traditional industry include water extraction and/or
juice expression to produce ready-to-drink concoctions.
Meanwhile, large herbal companies in Indonesia employ ethanolic extraction, followed by the drying process to produce an herbal powder with a long shelf life
[16]. This indicates the need to evaluate the activities of
both WLG and ethanolic extract of lemongrass (ELG).
In this study, the in vitro AGI activities of both WLG
and ELG were compared, and the extract with higher
activity was further evaluated for its in vivo activity and
subjected to a series of activity-guided fractionations to
isolate and identify the active compound(s). Therefore,
this study is expected to provide valuable insights into
Indonesian herbal industries and the use of lemongrass
as an herbal ingredient with AGI activity for the treatment of diabetes.

Materials and Methods
Materials. Dried lemongrass was purchased from a
plantation in Karang Anyar Lereng Lawu, Indonesia.
Distilled water and ethanol 96% technical grade were
obtained from Sumber Abadi, Serpong, Indonesia.
During the evaluation of in vitro AGI activity, the
following chemicals were used: sucrose and maltose
(Merck, Germany) analytical grade, potassium
phosphate (Merck, Germany), potassium dihydrogen
phosphate (Sinopharm Chemical Reagent Co.,
Shanghai), dimethyl sulfoxide (DMSO; Merck,
Germany), rat intestinal acetone powder (SigmaAldrich, Germany), ethylenediaminetetraacetic acid
(EDTA; Merck, Germany), aluminum oxide 60 (Merck,
Germany), tris(hydroxymethyl)aminomethane (Merck,
Germany), hydrochloric acid (HCl; PT. Smart Lab,
Indonesia), and glucose C-II test kit solution (Wako
Pure Chemical Co., Japan).
The materials used for in vivo evaluation include rat
intestinal acetone powder (Sigma-Aldrich, Germany),
sodium carboxymethyl cellulose (Brataco Chemika,
Indonesia), blood glucose test strip (glucometer;
GlucoDr® Auto, All Medicus Co., Ltd.), and mice feed
(pellet BR2). All other materials were analytical grade
and supplied by Merck, Germany. Adult male Swiss
mice weighing 20–30 g were procured from the Imono
Laboratory, Sanata Dharma University, Indonesia. The
mice were housed in standard cages under standard
laboratory conditions of 22 ± 2 °C and 12:12 h
Makara J. Sci.

light/dark cycle. Standard pellet diet and water were
given ad libitum. All procedures described were
reviewed and approved with approval number
KE/FK/1013/EC/2019 by the Medical and Health
Research Ethics Committee, Faculty of Medicine,
Gadjah Mada University–Dr. Sardjito General Hospital,
Yogyakarta, Indonesia.
The chemicals used for the isolation stage were nhexane analytical grade (Merck, Germany), methanol
analytical grade (Merck, Germany), ethyl acetate
analytical grade (Merck, Germany), thin layer
chromatography (TLC) silica gel 60 F254 (Merck,
Germany), and preparative thin-layer chromatography
(PLC) silica gel 60 F254 (Merck, Germany).
Lemongrass extraction. Dried lemongrass was
macerated using water and ethanol 96% for 24 h. The
dried lemongrass-to-solvent ratio was 3:5 (v/v). Crude
extracts were filtered using vacuum filtration and were
evaporated using a vacuum rotary evaporator at 50°C.
Then, both WLG and ELG were stored in a dark glass
bottle at 4 °C.
In vitro rat intestinal glucosidase inhibitory activity.
Glucosidase inhibitory activity analysis was conducted
using enzymatic reactions as previously described [17]
with some modifications. To produce the crude rat
intestinal glucosidase, 1 g rat intestinal acetone powder
was crushed until homogenous and mixed with 20 mL
of 0.1 M potassium phosphate buffer containing 5 mM
EDTA in a cold mortar on an ice bath to prevent
enzyme degradation. The mixture was placed in
prechilled centrifuge tubes and centrifuged for 60 min
(11,000 rpm, 4 °C). Any precipitation from
centrifugation was solubilized and centrifuged for a
second time in the same manner to increase efficiency.
The inhibitory activity against sucrose hydrolysis was
measured using the following procedures: Two test
tubes, as sample and control, containing 0.2 mL sucrose
solution (56 mM) in potassium phosphate buffer (0.1 M,
pH 7) and 2 test tubes, as sample and control blanks,
containing 0.4 mL potassium phosphate buffer (0.1 M,
pH 7) were preincubated at 37 °C for 5 min. The control
and control blank were defined as 100% and 0%
enzyme activity, respectively. Lemongrass extract
diluted in 50% DMSO (0.1 mL) was added to the
sample and sample blank test tubes; whereas 50%
DMSO (0.1 mL) was added to the control and control
blank test tubes. Then, crude rat intestinal glucosidase
(0.2 mL) was added only to the test tubes containing the
sucrose solution. The reaction was conducted at 37 ℃
for 15 min and terminated by adding Tris–HCl buffer (2
M, pH 6.3, 0.75 mL). Then, the reaction mixtures were
passed through a short column of basic alumina (30 mm
× 5 mm) to remove phenolics, which may interfere with
the subsequent glucose quantification. The mixture
December 2020  Vol. 24  No. 4
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(0.05 mL) was incubated with glucose C-II test kit
solution (0.2 mL) in 96-well microplate at 37 ℃ for 30
min. The optical density of the wells was measured at
492 nm. The inhibitory activity was calculated using the
following formula (Equation 1):
(1)
Equation 1. Formula for AGI activity calculation,
where C is the absorbance value for the control, Cb is
the absorbance value for the control blank, S is the
absorbance value for the sample, and Sb is the
absorbance value for the sample blank
The procedures for inhibitory activity assay against
maltose hydrolysis were the same as above, except for
replacing sucrose solution (56 mM, 0.2 mL) with
maltose solution (3.5 mM, 0.35 mL) and reducing the
amount of enzyme solution from 0.2 mL to 0.05 mL.
The experiments were conducted in two replications,
and the results were presented as half-maximum
inhibitory concentration (IC50). The slope test was
employed to determine IC50. Analysis of variance
(ANOVA) and Tukey’s HSD were used (α value =
0.05) to determine the highest inhibitory activity
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between WLG and ELG. The extract with the highest
AGI activity was selected for further tests.
In vivo sugar tolerance test. On the day of the
experiment, 80 mice were fasted overnight and
randomly divided into 16 groups, each consisting of 5
mice. One group was assigned as normal control (Group
C), five groups (SC, SA, S1, S2, and S3) were assigned
to the oral sucrose tolerance test (OSTT), five groups
(MC, MA, M1, M2, and M3) were assigned to the oral
maltose tolerance test (OMTT), and five groups (GC,
GA, G1, G2, and G3) were assigned to the oral glucose
tolerance test (OGTT).
Groups SC, MC, and GC served as sucrose control,
whereas Groups SA, MA, and GA received 0.08 g
acarbose/kg BW treatment. In OSTT, Groups S1, S2,
and S3 received 0.22, 0.67, and 2.00 g ELG/kg BW
treatments, respectively. Groups SC, SA, S1, S2, and S3
received 4 g sucrose/kg BW sugar induction (OSTT) 30
min after ELG or acarbose treatment. OMTT and OGTT
were conducted in the same manner as above, except for
replacing 4 g sucrose/kg BW with 3 g maltose/kg BW
for OMTT and 2 g glucose/kg BW for OGTT (Table 1).

Table 1. Treatments of Mice Groups
Mice Group

Sugar Challenge

Sample Treatment

Group Name

C

None

None

Normal Control

SC

None

Sucrose Control

SA

0.08 g acarbose/kg BW

Sucrose + Acarbose

0.22 g ELG/kg BW

Sucrose + ELG 0.22

S2

0.67 g ELG/kg BW

Sucrose + ELG 0.67

S3

2.00 g ELG/kg BW

Sucrose + ELG 2.00

MC

None

Maltose Control

MA

0.08 g acarbose/kg BW

Maltose + Acarbose

0.22 g ELG/kg BW

Maltose + ELG 0.22

M2

0.67 g ELG/kg BW

Maltose + ELG 0.67

M3

2.00 g ELG/kg BW

Maltose + ELG 2.00

GC

None

Glucose Control

GA

0.08 g acarbose/kg BW

Glucose + Acarbose

0.22 g ELG/kg BW

Glucose + ELG 0.22

G2

0.67 g ELG/kg BW

Glucose + ELG 0.67

G3

2.00 g ELG/kg BW

Glucose + ELG 2.00

S1

M1

G1

Makara J. Sci.

4 g sucrose/kg BW

3 g maltose/kg BW

2 g glucose/kg BW
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Blood was collected from the tail vein of the mice at 0
min before sugar induction and at 15, 30, 60, 90, and
120 min after sugar induction. Postprandial glucose
(PPG) levels were determined using a glucometer
[18,19].
The results are expressed as the mean ± standard
deviation. The trapezoidal rule was used to determine
the area under the curve (AUC) blood glucose
[20,21,22]. Data were analyzed using one-way
ANOVA, followed by post hoc Scheffe tests using
SPSS 22. A p value of <0.05 was considered
statistically significant. AUC was estimated using the
following formula for the trapezoidal rule (Equation 2):
(2)
Equation 2. Formula for AUC calculation of blood
glucose slope after sugar consumption, where t is the
time and C is the concentration of glucose
Isolation of α-glucosidase inhibiting principles. ELG
was gradually extracted using n-hexane, ethyl acetate,
and methanol. The resulting solutions were separately
evaporated and subjected to rat intestinal glucosidase
inhibitory activity assay. The fraction with the highest
AGI activity was further fractionated using reversedphase PLC (RP-PLC) (Supelco silica gel 60 RP-18 F254,
20 cm × 20 cm, 1 mm, Merck KGaA, Darmstadt,
Germany; mobile phase: ethyl acetate–methanol 4:1;
detection: UV 254 and 356 nm). This particular fraction
with the highest AGI activity was fractionated again
using RP-PLC (Supelco silica gel 60 RP-18 F254, 20 cm
× 20 cm, 1 mm, Merck KGaA, Darmstadt, Germany;
mobile phase: ethyl acetate–methanol 2:3; detection:
UV 254 and 356 nm) to isolate the bioactive compound.

HSS C18, 3.5 µm, 2.1 mm × 100 mm column at a
temperature of 40 ℃ and gradient eluent of methanol–
water 10:90 to 90:10 for 30 min, ES (positive) scanning).
Comparison with the pure standard was also conducted
using high-performance liquid chromatography (HPLC;
Agilent Technology, 1220 Infinity II LC; Column:
Zorbax Eclipse Plus 2.6 mm × 150 mm, 5 µm; mobile
phase: acetonitrile–glacial acetic acid–water (15:0.5:85,
v/v) with pH adjusted to 4.5, isocratic elution at a flow
rate of 1.0 mL/min; detection: UV 321 nm).

Results and Discussion
In vitro evaluation of -glucosidase inhibitory activity.
AGIs are expected to effectively inhibit postprandial
hyperglycemia by suppressing carbohydrate digestion
(Figure 2). In this study, AGI activity against the
digestion of sucrose and maltose was observed. In
conjunction with solvents commonly used in Indonesian
herbal industries, lemongrass was extracted using
ethanol 96% (ELG) and water (WLG). The inhibitory
activities of both extracts against the hydrolysis of
sucrose and maltose by rat intestinal α-glucosidase were
evaluated. The activities were expressed as IC50 to show
the concentration required to inhibit 50% of enzymatic
activity. ELG showed higher inhibitory activities
(Sucrase IC50 = 8.74 mg/mL; Maltase IC50 = 18.93
mg/mL) than WLG (Sucrase IC50 = 132.89 mg/mL;
Maltase IC50 = 302.27 mg/mL). Both extracts tend to
have high inhibitory activities against sucrose hydrolysis.
In a previous study, lemongrass had been extracted
using methanol, water, chloroform, and acetone.
Evaluation of AGI activities of the extracts showed that
methanol extract has the highest activity [15]. Due to
the proximity of methanol and ethanol polarities, the

The bioactive compound was analyzed using liquid
chromatography–mass spectrometry (LC-MS) (UPLC

Figure 2. Schematic Mechanism of the Retardation of PPG Elevation Due to the Inhibition of the Hydrolysis of Disaccharides to Glucose by AGI
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previous study was in agreement with the better activity
of ethanolic extraction in this study. This study
confirmed the lemongrass activities to inhibit the
hydrolysis of sucrose and maltose by intestinal
mammalian glucosidase enzyme with higher activity
extracted in ethanol as solvent. Due to its higher AGI
activity, ELG was selected for further tests.
In vivo evaluation of antihyperglycemic activity.
Sugar treatment increased the PPG level in mice 15 min
after administration. The AUC of the PPG level 120 min
after administration was compared between groups of
mice to evaluate the significant changes caused by the
treatments. Sugar treatments (SC, MC, and GC)
significantly increased the total PPG level in comparison
to the normal control group with no sugar treatment (C).
Before glucose was transported to the cells and stored as
a source of energy, glucose existed in the bloodstream
[23]. Acarbose is a common antihyperglycemic agent
that is used as a positive control in this study. Groups of
mice treated with acarbose (SA, MA, and GA) before
sugar administration have significantly lower total PPG
levels in comparison to those that are only receiving
sugar treatments (SC, MC, and GC), although the values
are still higher than C. Acarbose was shown to suppress
and decrease the spike of blood glucose as it inhibits the
breakdown of carbohydrate [24] and the absorption of
monosaccharides [25].
In OSTT, the total PPG elevation of mice treated with
acarbose and ELG (SA, S1, S2, and S3) was
significantly lower than that of mice in the sucrose
control group (SC) (Figure 3), confirming its
antihyperglycemic activity that inhibits the breakdown
of carbohydrate [26]. At the concentrations used in this
study (i.e., 0.22, 0.67, and 2.00 g/kg BW), ELG activity
was significantly lower than acarbose activity and did
not show a dose-dependent manner. Therefore, the
optimum effective dose in this study was 0.22 g/kg BW
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ELG (S1) treatment as it has a significantly lower total
PPG level compared with SC and a similar effect to
higher ELG doses (S2 and S3).
The PPG levels of SC continued to increase up to 15.7 ±
3.1 mmol/L 30 min after sucrose administration. The
PPG levels of SA, S1, S2, and S3 also increased but only
up to 15 min after sucrose administration and returned to
the basal level faster than SC. These results indicated
that ELG might also facilitate glucose clearance from
the blood vessel, adding another mechanism for its
postprandial antihyperglycemic activity [25].
In OMTT, ELG treatments at the concentrations used in
this study (M1, M2, and M3) were unable to reduce the
total PPG elevation in comparison to those untreated
maltose control (MC) (Figure 4). This result was
consistent with the result of the in vitro evaluation,
which showed that ELG has lower inhibitory activity
against maltose hydrolysis than sucrose hydrolysis.
Although ELG activity to inhibit maltose hydrolysis
was not shown as the AUC of the total PPG elevation,
M2 and M3 have significantly lower maximum PPG
levels (13.85 ± 2.3 and 15.46 ± 1.9 mmol/L,
respectively) than MC (17.4 ± 1.4 mmol/L) 15 min after
maltose administration. Groups of mice treated with a
low dose of ELG (M1) have a similar maximum PPG
level (17.5 ± 2.9 mmol/L) to MC. However, M1 was
able to delay the increase to 30 min after maltose
administration in comparison to MC (15 min after
maltose administration). ELG inhibits maltose digestion
and retards the absorption of glucose, thereby
preventing PPG spikes that are often associated with
atherosclerosis [27] and other complications [4].
Although M1 was unable to reduce the total PPG
elevation, the PPG level of mice treated with 0.67 and
2.00 g/kg BW (M2 and M3) returned to the basal state
faster than MC, indicating its mild activity in facilitating
glucose clearance from the blood vessel [25].

All treatments were done orally. The results are
presented as the average ± SD; a: p < 0.05 vs normal;
b: p < 0.05 vs sucrose; c: p < 0.05 vs acarbose.
Figure 3. Blood Glucose Reduction of Sucrose-induced Mice Over Time and Average AUC and Percentage of AUC Reduction of ELG after Sucrose Oral Induction in Mice (n = 5) from the Groups of Normal Control (C), Sucrose Control
(SC), Sucrose + Acarbose 0.08 g/kg BW (SA), Sucrose + ELG 0.22 g/kg BW (S1), Sucrose + ELG 0.67 g/kg BW
(S2), and Sucrose + ELG 2.00 g/kg BW (S3)
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All treatments were done orally. The results are
presented as the average ± SD; a: p < 0.05 vs
normal; b: p < 0.05 vs maltose; c: p < 0.05 vs
acarbose.
Figure 4. Blood Glucose Reduction of Maltose-induced Mice Over Time and Average AUC and Percentage of AUC Reduction of ELG after Maltose Oral Induction in Mice (n = 5) from the Groups of Normal Control (C), Maltose Control
(MC), Maltose + Acarbose 0.08 g/kg BW (MA), Maltose + ELG 0.22 g/kg BW (M1), Maltose + ELG 0.67 g/kg BW
(M2), and Maltose + ELG 2.00 g/kg BW (M3)

All treatments were done orally. The results are
presented as the average ± SD; a: p < 0.05 vs
normal; b: p < 0.05 vs glucose; c: p < 0.05 vs
acarbose.
Figure 5. Blood Glucose Reduction of Glucose-induced Mice Over Time and Average AUC and Percentage of AUC Reduction of ELG after Glucose Oral Induction in Mice (n = 5) from the Groups of Normal Control (C), Glucose Control
(GC), Glucose + Acarbose 0.08 g/kg BW (GA), Glucose + ELG 0.22 g/kg BW (G1), Glucose + ELG 0.67 g/kg BW
(M2), and Glucose + ELG 2.00 g/kg BW (M3)

ELG activities that prevent PPG spikes after sucrose and
maltose consumption and total PPG elevation after
sucrose consumption confirmed its in vivo AGI activity
that inhibits digestive enzymes from breaking down
disaccharides. The in vivo result was consistent with the
in vitro result, indicating the stronger activity of ELG to
inhibit sucrose hydrolysis than maltose hydrolysis
(Figure 3). The non-dose-dependent manner of the
activity showed that ELG activity is also correlated with
glucose counterregulatory responses to hypoglycemia
[26, 28]. The fast PPG level reduction to its basal state
indicated that ELG might also have cell glucose uptake
activity that is also preferable for the treatment of
hyperglycemia [29–30]. Therefore, OGTT was further
conducted to confirm this activity.
In OGTT, ELG at doses of 0.22 and 2.00 mg/kg BW
(G1 and G3) were surprisingly able to reduce the total
Makara J. Sci.

PPG elevation in comparison to glucose control (GC)
with a similar level to acarbose (GA), whereas ELG at a
dose of 0.67 mg/kg BW (G2) did not (Figure 5). Again,
the ELG activity did not show a dose-dependent
manner, and the 0.22 mg/kg dose was once again shown
to be a better treatment option because of its similar or
even stronger effect on PPG level reduction compared
with higher doses. Glucose counterregulatory responses
to hypoglycemia at higher doses in healthy individuals
might be responsible for the observed result in G2 mice
[26,28]. Glucose, which is derived from the diet and
synthesized by the body, needs a transporter, such as
SGLT and GLUT, to be distributed to the bloodstream
and cells [31]. Several mechanisms for the antihyperglycemic activity of lemongrass extract against glucose
induction include the inhibition of the glucose transporter
and the acceleration of the number of glucose transporters
[32,33,34]. ELG activities that inhibit both PPG spike
December 2020  Vol. 24  No. 4
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and total PPG elevation in OGTT showed that ELG not
only inhibits disaccharides from hydrolyzing enzymes
but also reduces the glucose transporter that transports
glucose from the digestive tract to the blood vessel
and/or increases cell glucose uptake that facilitates
glucose clearance from the blood vessel.
Isolation of -glucosidase inhibiting principles.
Bioactive compounds responsible for the AGI activity
were isolated using activity-guided fractionation (Figure
1). ELG (13.90 g) was fractionated using n-hexane,
ethyl acetate, and methanol, yielding a 3.99 g n-hexanesoluble fraction (ELG-He), a 2.01 g ethyl-acetate-soluble
fraction (ELG-Et), and a 5.57 g methanol-soluble
fraction (ELG-Me). ELG-Me exhibited the highest AGI
activity (60.67 ± 3.46%) at a concentration of 1 mg/mL,
whereas ELG-He and ELG-Et only showed 40.22 ±
2.30% and 43.78 ± 1.57% inhibition, respectively.
The active fraction (ELG-Me) was subjected to PLC
fractionation using ethyl acetate–methanol (4:1) as the
mobile phase. Collected fractions were subjected to AGI
activity assay. The active fractions with 42.39 ± 4.24%
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AGI activity (ELG-Me-V, Rf = 0.03–0.25, 890 mg) was
further subjected to LC-MS evaluation, and the resulting
compound with the mass spectrum of m/z 182.80 was
identified as caffeic acid (C9H8O4) with the molecular
mass of 180.16 and the mass spectrum of m/z 285.37
was identified as kaempferol (C15H10O6) with the
molecular mass of 286.23 (Figure 6). The RP-PLC
purified fraction (ELG-Me-V-3) was further compared
with the standard in HPLC to confirm the isolation of
caffeic acid.
Kaempferol and caffeic acid were previously identified
to be present in lemongrass [8]. Moreover, research
conducted by Zang et al. in 2011 and Chandramohan et
al. in 2015 showed that kaempferol exhibited an
antidiabetic effect by increasing the insulin level and
decreasing the plasma glucose of diabetic rats [35,36].
Another research showed that caffeic acid was also able
to lower the blood glucose of diabetic rats [37]. The
finding of this study indicated the potential use of ELG
in the management of hyperglycemia.

Figure 1. Extraction and Fractionation Scheme of ELG for the Isolation of the -glucosidase Inhibiting Principles
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Figure 6. Chemical Structures of (1) Caffeic Acid and (2) Kaempferol Identified in the Active Fraction of ELG

Conclusion
The AGI principles in lemongrass were better extracted
in the ethanolic solvent. ELG showed a non-dosedependent manner of inhibition of PPG elevation
following all sugar challenges tested in this study,
namely, sucrose, maltose, and glucose, with the lowest
dose of 0.22 g/kg BW treatment showing the most
optimum result. Further fractionation and identification
of the bioactive compounds resulted in the identification
of caffeic acid and kaempferol as the α-glucosidase
inhibiting principles of ELG. This finding suggests the
utilization of lemongrass in traditional and complementary
medicine in the management of diabetes.
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